Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07791199 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07791199 · ClinicalTrials.gov record · last posted 2026-08-27

Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers

Name: Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers — clinical trial record (NCT07791199)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorBristol-Myers Squibb

Started2026-09-02

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable.

Trial Details

NCT Number	NCT07791199
Lead Sponsor	Bristol-Myers Squibb
Conditions	Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis
Enrollment	2,300 participants
Start Date	2026-09-02
Primary Completion	2030-10-31 (estimated)
Study Completion	2030-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-27